China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. reports that its subsidiary, Dong-E-E-Jiao, achieved a significant rise in revenue and net profit for the first nine months of 2024, with revenue reaching RMB 4.33 billion and net profit climbing to RMB 1.15 billion. However, the company saw a decrease in cash and cash equivalents, highlighting potential liquidity challenges. Investors are advised to approach with caution as these financials are unaudited.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
